<?xml version="1.0" encoding="UTF-8"?><safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-39</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150220</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150206</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150206</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>Literature</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb/>
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-39</companynumb>
		<duplicate/>
		<casenullification/>
		<nullificationreason/>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle/>
			<reportergivename>E</reportergivename>
			<reportermiddlename/>
			<reporterfamilyname>Nanishi</reporterfamilyname>
			<reporterorganization/>
			<reporterdepartment/>
			<reporterstreet/>
			<reportercity/>
			<reporterstate/>
			<reporterpostcode/>
			<reportercountry>JP</reportercountry>
			<qualification>3</qualification>
			<literaturereference>Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary EpsteineBarr virus infection. Journal of Microbiology, Immunology and Infection. 2015;48:109-112</literaturereference>
			<studyname/>
			<sponsorstudynumb/>
			<observestudytype/>
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename/>
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate/>
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype/>
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment/>
			<receivertitle/>
			<receivergivename/>
			<receivermiddlename/>
			<receiverfamilyname/>
			<receiverstreetaddress/>
			<receivercity/>
			<receiverstate/>
			<receiverpostcode/>
			<receivercountrycode/>
			<receivertel/>
			<receivertelextension/>
			<receivertelcountrycode/>
			<receiverfax/>
			<receiverfaxextension/>
			<receiverfaxcountrycode/>
			<receiveremailaddress/>
		</receiver>
		<patient>
			<patientinitial>UNK</patientinitial>
			<patientgpmedicalrecordnumb/>
			<patientspecialistrecordnumb/>
			<patienthospitalrecordnumb/>
			<patientinvestigationnumb/>
			<patientbirthdateformat/>
			<patientbirthdate/>
			<patientonsetage/>
			<patientonsetageunit/>
			<gestationperiod/>
			<gestationperiodunit/>
			<patientagegroup/>
			<patientweight/>
			<patientheight/>
			<patientsex/>
			<lastmenstrualdateformat/>
			<patientlastmenstrualdate/>
			<patientmedicalhistorytext/>
			<resultstestsprocedures/>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10015108</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue/>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Drug reaction with eosinophilia and systemic symptoms</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10073508</reactionmeddrallt>
				<reactionmeddraversionpt/>
				<reactionmeddrapt/>
				<termhighlighted/>
				<reactionstartdateformat/>
				<reactionstartdate/>
				<reactionenddateformat/>
				<reactionenddate/>
				<reactionduration/>
				<reactiondurationunit/>
				<reactionfirsttime/>
				<reactionfirsttimeunit/>
				<reactionlasttime/>
				<reactionlasttimeunit/>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<test>
				<testdateformat/>
				<testdate/>
				<testname>Lymphocyte transformation test</testname>
				<testresult>positive for cefditoren-pivoxil and acetaminophen</testresult>
				<testunit>Report</testunit>
				<lowtestrange/>
				<hightestrange/>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PARACETAMOL</medicinalproduct>
				<obtaindrugcountry>RO</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry/>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform/>
				<drugadministrationroute>65</drugadministrationroute>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessed</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Cefditoren</medicinalproduct>
				<obtaindrugcountry>IN</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry/>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform/>
				<drugadministrationroute>65</drugadministrationroute>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10057097</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>5</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>CEFDITOREN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10073508</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessed</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This case, manufacturer control number 2015RR-93179, from JAPAN, refers to a patient of unspecified age or gender who developed drug reaction with eosinophilia and systemic symptoms following treatment with cefditoren pivoxil and acetaminophen.The case was reported in literature.The case was considered serious because the ADR was medically significant.Patient current condition:Epstein-Barr virus infection.The patient received the following suspect products:Cefditoren pivoxil: for unknown indication.Acetaminophen: for unknown indication.On an unspecified date, the patient developed drug reaction with eosinophilia and systemic symptoms following treatment with cefditoren pivoxil and acetaminophen.Reaction text: "We report a drug reaction with eosinophilia and systemic symptoms case of primary Epstein-Barr virus (EBV) infection, in which the diagnosis was first confirmed by lymphocyte transformation tests (LTT). LTTs were positive for cefditoren-pivoxil and acetaminophen. LTT, EBV load, and anti-EBV antibodies could allow early diagnosis of drug reaction with eosinophilia and systemic symptoms, which masquerades with the clinical features of infectious mononucleosis."The outcome of the ADR was not reported at the time of this report.Ranbaxy medical reviewer's assessment:The case is rated as serious and unexpected with Acetaminophen use in EU.The causal role of Acetaminophen and Cefditoren pivoxil cannot be properly assessed as insufficient data is provided regarding  dose, route of administration, frequency and indication of suspected drugs, time onset of ADR, patient's medical history and concomitant medication. Further details are required in order to proper evaluate the report.The SPC of Acetaminophen lists cutaneous hypersensitivity reactions but does not list drug reaction with eosinophilia and systemic symptoms (which is a more specific form of hypersensitivity).</narrativeincludeclinical>
				<reportercomment/>
				<senderdiagnosismeddraversion>17.1</senderdiagnosismeddraversion>
				<senderdiagnosis>10073508</senderdiagnosis>
				<sendercomment>The case is rated as serious and unexpected with Acetaminophen use in EU.The causal role of Acetaminophen and Cefditoren pivoxil cannot be properly assessed as insufficient data is provided regarding  dose, route of administration, frequency and indication of suspected drugs, time onset of ADR, patient's medical history and concomitant medication. Further details are required in order to proper evaluate the report.The SPC of Acetaminophen lists cutaneous hypersensitivity reactions but does not list drug reaction with eosinophilia and systemic symptoms (which is a more specific form of hypersensitivity).</sendercomment>
			</summary>
		</patient>
	</safetyreport>